D-Dimer与胰腺癌Ⅳ期患者生存期及预后的相关性研究
| 作者: |
1王婧,
1赵磊,
1车娟娟,
1李卉惠,
1吴军,
1庞歆桥,
1马妮娜
1 首都医科大学附属北京友谊医院肿瘤科，北京 100050 |
| 通讯: |
马妮娜
Email: manina1970@sina.com |
| DOI: | 10.3978/j.issn.2095-6959.2016.05.008 |
| 基金: | 北京市医院管理局“青苗”计划专项经费资助, QML20150107 北京市中医药科技发展资金项目资助, QN2015-08 首都医科大学基础-临床合作课题资助项目, 14JL31 首都医科大学附属北京友谊医院院启动基金资助, yyqdkt2014-10 首都卫生发展科研专项基金资助, 2016-4-1112 |
摘要
目的：探讨Ⅳ期胰腺癌患者血浆中D-二聚体(D-Dimer)水平与患者预后的相关性。方法：本研究回顾性分析了2001年1月至2015年12月在首都医科大学附属北京友谊医院治疗的胰腺癌住院患者90例，分析其入院时血浆D-Dimer、纤维蛋白原(fibrinogen，Fbg)含量与临床特征及总生存时间的关系。结果：Ⅳ期胰腺癌患者中D-Dimer水平升高、Fbg含量降低者生存期相对较短，体能状态评分相对较差。ECOG≥3分患者D-Dimer[(5.40±3.19) mg/L]显著高于ECOG≤2分患者[(2.42±2.33)mg/L] (P<0.01)。D-Dimer水平正常者OS为9.82个月(95% CI，8.42~11.26个月)，D-Dimer水平异常者OS为3.76个月(95% CI，3.11~4.40个月)，二者差异有统计学意义(P<0.05)。D-Dimer水平为胰腺癌患者预后独立危险因素。结论：D-Dimer可作为Ⅳ期胰腺癌患者预后判断的实验室指标，其异常升高提示患者预后较差。
关键词：
D-二聚体
胰腺癌
预后
Correlation analysis of plasma D-Dimer level with survival and prognosis in stage Ⅳ pancreatic cancer patients
CorrespondingAuthor: MA Nina Email: manina1970@sina.com
DOI: 10.3978/j.issn.2095-6959.2016.05.008
Abstract
Objective: To examine the association of plasma D-Dimer levels and the prognosis of stage Ⅳ pancreatic cancer patients. Methods: Retrospectively analysed 90 stage Ⅳ pancreatic cancer patients hospitalized in Beijing Friendship Hospital Affiliated Capital Medical University from January 2001 to December 2015, the correlation between plasma D-Dimer levels, the content of Fbg with clinical features and overall survival were analysed. Results: In stage Ⅳ pancreatic cancer patients’ D-Dimer levels increased, Fbg levels decreased, relatively the survival period was short and patients had poor physical status; D-Dimer in patients with ECOG ≥3 [(5.40±3.19) mg/L] was significantly higher than those with ECOG ≤2 [(2.42±2.33) mg/L] (P<0.01). The OS of patients with normal D-Dimer level was 9.82 months (95% CI, 8.42~11.26 months), with abnormal was
3.76 months (95% CI, 3.11~4.40 months) (P<0.05). Multivariate analysis revealed that D-Dimer was a significant independent factor for OS in stage Ⅳ pancreatic cancer. Conclusion: D-Dimer could be the laboratory indexes of judging the prognosis of patients with stage Ⅳ pancreatic cancer, which abnormally elevated prompted patients with poor prognosis.
3.76 months (95% CI, 3.11~4.40 months) (P<0.05). Multivariate analysis revealed that D-Dimer was a significant independent factor for OS in stage Ⅳ pancreatic cancer. Conclusion: D-Dimer could be the laboratory indexes of judging the prognosis of patients with stage Ⅳ pancreatic cancer, which abnormally elevated prompted patients with poor prognosis.